Artia Global Partners LP Takes $4.68 Million Position in Palisade Bio, Inc. $PALI

Artia Global Partners LP purchased a new stake in shares of Palisade Bio, Inc. (NASDAQ:PALI) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 1,992,367 shares of the company’s stock, valued at approximately $4,682,000. Palisade Bio makes up about 0.6% of Artia Global Partners LP’s investment portfolio, making the stock its 23rd biggest position. Artia Global Partners LP owned about 1.34% of Palisade Bio as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Balyasny Asset Management L.P. bought a new position in shares of Palisade Bio during the 4th quarter valued at $765,000. Boothbay Fund Management LLC bought a new position in shares of Palisade Bio during the 4th quarter valued at $312,000. ACT Capital Management LLC bought a new position in shares of Palisade Bio during the 4th quarter valued at $352,000. ADAR1 Capital Management LLC bought a new position in shares of Palisade Bio during the 4th quarter valued at $4,711,000. Finally, Schonfeld Strategic Advisors LLC bought a new position in shares of Palisade Bio during the 4th quarter valued at $26,000. Institutional investors own 11.79% of the company’s stock.

Palisade Bio Price Performance

NASDAQ PALI opened at $1.76 on Thursday. The firm has a market capitalization of $305.50 million, a price-to-earnings ratio of -1.74 and a beta of 1.52. The company’s fifty day moving average is $1.97 and its two-hundred day moving average is $1.90. Palisade Bio, Inc. has a 52-week low of $0.53 and a 52-week high of $2.86.

Palisade Bio (NASDAQ:PALI) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). As a group, sell-side analysts expect that Palisade Bio, Inc. will post -0.21 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on PALI shares. Wall Street Zen upgraded shares of Palisade Bio from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Stifel Nicolaus began coverage on shares of Palisade Bio in a research note on Wednesday, February 25th. They issued a “buy” rating and a $5.00 target price on the stock. HC Wainwright began coverage on shares of Palisade Bio in a report on Thursday, March 26th. They issued a “buy” rating and a $7.00 target price on the stock. Wolfe Research began coverage on shares of Palisade Bio in a report on Thursday, April 9th. They issued an “outperform” rating and a $7.00 target price on the stock. Finally, Weiss Ratings downgraded shares of Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $10.20.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.